Haemonetics Revenue vs. Net Income
| HAE Stock | USD 82.77 0.66 0.80% |
Total Revenue | First Reported 1990-06-30 | Previous Quarter 321.4 M | Current Value 327.3 M | Quarterly Volatility 88.8 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.57 | 0.5283 |
|
| |||||
| Net Profit Margin | 0.0834 | 0.0898 |
|
| |||||
| Operating Profit Margin | 0.13 | 0.126 |
|
| |||||
| Pretax Profit Margin | 0.12 | 0.116 |
|
| |||||
| Return On Assets | 0.0694 | 0.0535 |
|
| |||||
| Return On Equity | 0.11 | 0.1225 |
|
|
For Haemonetics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Haemonetics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Haemonetics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Haemonetics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Haemonetics over time as well as its relative position and ranking within its peers.
Haemonetics | Build AI portfolio with Haemonetics Stock |
Haemonetics' Revenue Breakdown by Earning Segment
Check out Risk vs Return Analysis.
Haemonetics Revenue Breakdown by Earning Segment
By analyzing Haemonetics' earnings estimates, investors can diagnose different trends across Haemonetics' analyst sentiment over time as well as compare current estimates against different timeframes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.227 | Earnings Share 3.42 | Revenue Per Share | Quarterly Revenue Growth (0.05) | Return On Assets |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Haemonetics Net Income vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Haemonetics's current stock value. Our valuation model uses many indicators to compare Haemonetics value to that of its competitors to determine the firm's financial worth. Haemonetics is rated below average in revenue category among its peers. It is one of the top stocks in net income category among its peers making up about 0.12 of Net Income per Revenue. The ratio of Revenue to Net Income for Haemonetics is roughly 8.12 . At present, Haemonetics' Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Haemonetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Haemonetics Revenue vs. Competition
Haemonetics is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 23.74 Billion. Haemonetics holds roughly 1.36 Billion in revenue claiming about 6% of equities under Health Care industry.
Haemonetics Net Income vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Haemonetics |
| = | 1.36 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Haemonetics |
| = | 167.68 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Haemonetics Net Income Comparison
Haemonetics is currently under evaluation in net income category among its peers.
Haemonetics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Haemonetics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Haemonetics will eventually generate negative long term returns. The profitability progress is the general direction of Haemonetics' change in net profit over the period of time. It can combine multiple indicators of Haemonetics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -63.3 M | -60.2 M | |
| Operating Income | 255.1 M | 267.8 M | |
| Total Other Income Expense Net | -11.2 M | -11.8 M | |
| Net Income | 192.8 M | 202.5 M | |
| Income Before Tax | 243.9 M | 256.1 M | |
| Income Tax Expense | 51.1 M | 53.6 M | |
| Net Income Applicable To Common Shares | 192.8 M | 202.5 M | |
| Net Income From Continuing Ops | 192.8 M | 202.5 M | |
| Non Operating Income Net Other | -13.2 M | -13.8 M | |
| Interest Income | 11.2 M | 13.2 M | |
| Net Interest Income | -8.8 M | -9.2 M | |
| Change To Netincome | 41.6 M | 40.4 M | |
| Net Income Per Share | 2.32 | 2.43 | |
| Income Quality | 1.55 | 1.47 | |
| Net Income Per E B T | 0.77 | 0.44 |
Haemonetics Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Haemonetics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Haemonetics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Haemonetics' important profitability drivers and their relationship over time.
Haemonetics Earnings Estimation Breakdown
The calculation of Haemonetics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Haemonetics is estimated to be 1.25 with the future projection ranging from a low of 1.18 to a high of 1.28. Please be aware that this consensus of annual earnings estimates for Haemonetics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.18 Lowest | Expected EPS | 1.28 Highest |
Haemonetics Earnings Projection Consensus
Suppose the current estimates of Haemonetics' value are higher than the current market price of the Haemonetics stock. In this case, investors may conclude that Haemonetics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Haemonetics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 11 | 91.15% | 1.27 | 1.25 | 3.42 |
Haemonetics Earnings History
Earnings estimate consensus by Haemonetics analysts from Wall Street is used by the market to judge Haemonetics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Haemonetics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Haemonetics Quarterly Gross Profit |
|
Haemonetics Earnings per Share Projection vs Actual
Actual Earning per Share of Haemonetics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Haemonetics predict the company's earnings will be in the future. The higher the earnings per share of Haemonetics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Haemonetics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Haemonetics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Haemonetics should always be considered in relation to other companies to make a more educated investment decision.Haemonetics Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Haemonetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-06 | 2025-09-30 | 1.11 | 1.27 | 0.16 | 14 | ||
2025-08-07 | 2025-06-30 | 1.02 | 1.1 | 0.08 | 7 | ||
2025-05-08 | 2025-03-31 | 1.22 | 1.24 | 0.02 | 1 | ||
2025-02-06 | 2024-12-31 | 1.17 | 1.19 | 0.02 | 1 | ||
2024-11-07 | 2024-09-30 | 1.07 | 1.12 | 0.05 | 4 | ||
2024-08-08 | 2024-06-30 | 1.01 | 1.02 | 0.01 | 0 | ||
2024-05-09 | 2024-03-31 | 0.89 | 0.9 | 0.01 | 1 | ||
2024-02-08 | 2023-12-31 | 0.94 | 1.04 | 0.1 | 10 | ||
2023-11-02 | 2023-09-30 | 0.89 | 0.99 | 0.1 | 11 | ||
2023-08-08 | 2023-06-30 | 0.73 | 1.05 | 0.32 | 43 | ||
2023-05-11 | 2023-03-31 | 0.7 | 0.77 | 0.07 | 10 | ||
2023-02-07 | 2022-12-31 | 0.82 | 0.85 | 0.03 | 3 | ||
2022-11-07 | 2022-09-30 | 0.67 | 0.83 | 0.16 | 23 | ||
2022-08-10 | 2022-06-30 | 0.51 | 0.58 | 0.07 | 13 | ||
2022-05-10 | 2022-03-31 | 0.6 | 0.65 | 0.05 | 8 | ||
2022-02-08 | 2021-12-31 | 0.73 | 0.84 | 0.11 | 15 | ||
2021-11-09 | 2021-09-30 | 0.61 | 0.6 | -0.01 | 1 | ||
2021-08-11 | 2021-06-30 | 0.45 | 0.5 | 0.05 | 11 | ||
2021-05-13 | 2021-03-31 | 0.67 | 0.46 | -0.21 | 31 | ||
2021-02-02 | 2020-12-31 | 0.65 | 0.81 | 0.16 | 24 | ||
2020-11-04 | 2020-09-30 | 0.51 | 0.62 | 0.11 | 21 | ||
2020-08-04 | 2020-06-30 | 0.41 | 0.46 | 0.05 | 12 | ||
2020-05-05 | 2020-03-31 | 0.73 | 0.69 | -0.04 | 5 | ||
2020-02-04 | 2019-12-31 | 0.76 | 0.94 | 0.18 | 23 | ||
2019-11-01 | 2019-09-30 | 0.72 | 0.87 | 0.15 | 20 | ||
2019-08-06 | 2019-06-30 | 0.64 | 0.81 | 0.17 | 26 | ||
2019-05-07 | 2019-03-31 | 0.55 | 0.61 | 0.06 | 10 | ||
2019-02-05 | 2018-12-31 | 0.59 | 0.63 | 0.04 | 6 | ||
2018-11-06 | 2018-09-30 | 0.54 | 0.56 | 0.02 | 3 | ||
2018-08-07 | 2018-06-30 | 0.42 | 0.59 | 0.17 | 40 | ||
2018-05-08 | 2018-03-31 | 0.43 | 0.43 | 0.0 | 0 | ||
2018-02-06 | 2017-12-31 | 0.44 | 0.62 | 0.18 | 40 | ||
2017-11-07 | 2017-09-30 | 0.41 | 0.48 | 0.07 | 17 | ||
2017-08-07 | 2017-06-30 | 0.3 | 0.33 | 0.03 | 10 | ||
2017-05-08 | 2017-03-31 | 0.38 | 0.39 | 0.01 | 2 | ||
2017-02-06 | 2016-12-31 | 0.4 | 0.43 | 0.03 | 7 | ||
2016-11-07 | 2016-09-30 | 0.35 | 0.46 | 0.11 | 31 | ||
2016-08-01 | 2016-06-30 | 0.29 | 0.25 | -0.04 | 13 | ||
2016-05-02 | 2016-03-31 | 0.46 | 0.37 | -0.09 | 19 | ||
2016-02-01 | 2015-12-31 | 0.45 | 0.48 | 0.03 | 6 | ||
2015-11-04 | 2015-09-30 | 0.4 | 0.44 | 0.04 | 10 | ||
2015-07-27 | 2015-06-30 | 0.31 | 0.35 | 0.04 | 12 | ||
2015-04-27 | 2015-03-31 | 0.52 | 0.47 | -0.05 | 9 | ||
2015-01-29 | 2014-12-31 | 0.51 | 0.53 | 0.02 | 3 | ||
2014-11-03 | 2014-09-30 | 0.45 | 0.47 | 0.02 | 4 | ||
2014-07-30 | 2014-06-30 | 0.35 | 0.38 | 0.03 | 8 | ||
2014-04-28 | 2014-03-31 | 0.58 | 0.46 | -0.12 | 20 | ||
2014-01-27 | 2013-12-31 | 0.6 | 0.61 | 0.01 | 1 | ||
2013-10-28 | 2013-09-30 | 0.55 | 0.66 | 0.11 | 20 | ||
2013-07-29 | 2013-06-30 | 0.39 | 0.46 | 0.07 | 17 | ||
2013-05-01 | 2013-03-31 | 0.46 | 0.48 | 0.02 | 4 | ||
2013-01-30 | 2012-12-31 | 0.48 | 0.5 | 0.02 | 4 | ||
2012-10-29 | 2012-09-30 | 0.39 | 0.45 | 0.06 | 15 | ||
2012-08-01 | 2012-06-30 | 0.35 | 0.28 | -0.07 | 20 | ||
2012-04-29 | 2012-03-31 | 0.42 | 0.4 | -0.02 | 4 | ||
2012-01-30 | 2011-12-31 | 0.4 | 0.43 | 0.03 | 7 | ||
2011-10-31 | 2011-09-30 | 0.39 | 0.36 | -0.03 | 7 | ||
2011-08-01 | 2011-06-30 | 0.39 | 0.33 | -0.06 | 15 | ||
2011-05-02 | 2011-03-31 | 0.42 | 0.43 | 0.01 | 2 | ||
2011-01-31 | 2010-12-31 | 0.41 | 0.45 | 0.04 | 9 | ||
2010-11-01 | 2010-09-30 | 0.38 | 0.4 | 0.02 | 5 | ||
2010-08-02 | 2010-06-30 | 0.36 | 0.37 | 0.01 | 2 | ||
2010-05-04 | 2010-03-31 | 0.38 | 0.38 | 0.0 | 0 | ||
2010-02-01 | 2009-12-31 | 0.36 | 0.36 | 0.0 | 0 | ||
2009-11-02 | 2009-09-30 | 0.32 | 0.35 | 0.03 | 9 | ||
2009-08-03 | 2009-06-30 | 0.33 | 0.35 | 0.02 | 6 | ||
2009-05-04 | 2009-03-31 | 0.32 | 0.33 | 0.01 | 3 | ||
2009-02-02 | 2008-12-31 | 0.3 | 0.32 | 0.02 | 6 | ||
2008-10-27 | 2008-09-30 | 0.26 | 0.29 | 0.03 | 11 | ||
2008-08-01 | 2008-06-30 | 0.27 | 0.3 | 0.03 | 11 | ||
2008-05-01 | 2008-03-31 | 0.29 | 0.29 | 0.0 | 0 | ||
2008-01-31 | 2007-12-31 | 0.27 | 0.28 | 0.01 | 3 | ||
2007-11-01 | 2007-09-30 | 0.23 | 0.23 | 0.0 | 0 | ||
2007-08-02 | 2007-06-30 | 0.25 | 0.25 | 0.0 | 0 | ||
2007-05-02 | 2007-03-31 | 0.26 | 0.36 | 0.1 | 38 | ||
2007-01-31 | 2006-12-31 | 0.24 | 0.25 | 0.01 | 4 | ||
2006-10-31 | 2006-09-30 | 0.22 | 0.2 | -0.02 | 9 | ||
2006-07-27 | 2006-06-30 | 0.25 | 0.22 | -0.03 | 12 | ||
2006-05-03 | 2006-03-31 | 0.28 | 0.31 | 0.03 | 10 | ||
2006-01-30 | 2005-12-31 | 0.23 | 0.25 | 0.02 | 8 | ||
2005-10-27 | 2005-09-30 | 0.19 | 0.2 | 0.01 | 5 | ||
2005-07-28 | 2005-06-30 | 0.19 | 0.24 | 0.05 | 26 | ||
2005-05-05 | 2005-03-31 | 0.18 | 0.19 | 0.01 | 5 | ||
2005-01-31 | 2004-12-31 | 0.18 | 0.23 | 0.05 | 27 | ||
2004-11-01 | 2004-09-30 | 0.17 | 0.17 | 0.0 | 0 | ||
2004-07-29 | 2004-06-30 | 0.19 | 0.19 | 0.0 | 0 | ||
2004-05-03 | 2004-03-31 | 0.19 | 0.19 | 0.0 | 0 | ||
2004-01-22 | 2003-12-31 | 0.17 | 0.19 | 0.02 | 11 | ||
2003-10-23 | 2003-09-30 | 0.14 | 0.12 | -0.02 | 14 | ||
2003-07-24 | 2003-06-30 | 0.12 | 0.11 | -0.01 | 8 | ||
2003-04-23 | 2003-03-31 | 0.12 | 0.09 | -0.03 | 25 | ||
2003-01-23 | 2002-12-31 | 0.17 | 0.21 | 0.04 | 23 | ||
2002-10-24 | 2002-09-30 | 0.13 | 0.14 | 0.01 | 7 | ||
2002-07-24 | 2002-06-30 | 0.13 | 0.13 | 0.0 | 0 | ||
2002-05-02 | 2002-03-31 | 0.14 | 0.14 | 0.0 | 0 | ||
2002-01-24 | 2001-12-31 | 0.17 | 0.18 | 0.01 | 5 | ||
2001-10-25 | 2001-09-30 | 0.14 | 0.19 | 0.05 | 35 | ||
2001-07-26 | 2001-06-30 | 0.15 | 0.19 | 0.04 | 26 | ||
2001-05-03 | 2001-03-31 | 0.14 | 0.14 | 0.0 | 0 | ||
2001-01-25 | 2000-12-31 | 0.15 | 0.17 | 0.02 | 13 | ||
2000-10-26 | 2000-09-30 | 0.14 | 0.13 | -0.01 | 7 | ||
2000-07-27 | 2000-06-30 | 0.13 | 0.13 | 0.0 | 0 | ||
2000-05-04 | 2000-03-31 | 0.14 | 0.14 | 0.0 | 0 | ||
2000-01-27 | 1999-12-31 | 0.13 | 0.13 | 0.0 | 0 | ||
1999-10-28 | 1999-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
1999-07-29 | 1999-06-30 | 0.09 | 0.11 | 0.02 | 22 | ||
1999-05-06 | 1999-03-31 | 0.09 | 0.12 | 0.03 | 33 | ||
1999-01-29 | 1998-12-31 | 0.1 | 0.09 | -0.01 | 10 | ||
1998-10-26 | 1998-09-30 | 0.08 | 0.1 | 0.02 | 25 | ||
1998-07-27 | 1998-06-30 | 0.08 | 0.1 | 0.02 | 25 | ||
1998-05-04 | 1998-03-31 | 0.11 | -0.06 | -0.17 | 154 | ||
1998-01-27 | 1997-12-31 | 0.11 | 0.09 | -0.02 | 18 | ||
1997-10-16 | 1997-09-30 | 0.11 | 0.08 | -0.03 | 27 | ||
1997-04-15 | 1997-03-31 | 0.13 | 0.14 | 0.01 | 7 | ||
1997-01-14 | 1996-12-31 | 0.13 | 0.13 | 0.0 | 0 | ||
1996-10-11 | 1996-09-30 | 0.17 | 0.16 | -0.01 | 5 | ||
1996-07-15 | 1996-06-30 | 0.16 | 0.17 | 0.01 | 6 | ||
1996-04-18 | 1996-03-31 | 0.17 | 0.17 | 0.0 | 0 | ||
1996-01-15 | 1995-12-31 | 0.16 | 0.16 | 0.0 | 0 | ||
1995-10-15 | 1995-09-30 | 0.16 | 0.17 | 0.01 | 6 | ||
1995-07-16 | 1995-06-30 | 0.16 | 0.16 | 0.0 | 0 |
Use Haemonetics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Haemonetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Haemonetics will appreciate offsetting losses from the drop in the long position's value.Haemonetics Pair Trading
Haemonetics Pair Trading Analysis
The ability to find closely correlated positions to Haemonetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Haemonetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Haemonetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Haemonetics to buy it.
The correlation of Haemonetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Haemonetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Haemonetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Haemonetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Haemonetics position
In addition to having Haemonetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Beers Thematic Idea Now
Beers
Companies involved in production and distribution of domestic and international beer. The Beers theme has 34 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
To fully project Haemonetics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Haemonetics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Haemonetics' income statement, its balance sheet, and the statement of cash flows.